Literature DB >> 23242469

CD133 expression in osteosarcoma and derivation of CD133⁺ cells.

Ji Li1, Xiao-Yan Zhong, Zong-Yu Li, Jin-Fang Cai, Lin Zou, Jian-Min Li, Tao Yang, Wei Liu.   

Abstract

Cluster of differentiation 133 (CD133) is recognized as a stem cell marker for normal and cancerous tissues. Using cell culture and real‑time fluorescent polymerase chain reaction, CD133 expression was analyzed in osteosarcoma tissue and Saos‑2 cell lines. In addition, cancer stem cell‑related gene expression in the Saos‑2 cell line was determined to explore the mechanisms underlying tumorigenesis and high drug resistance in osteosarcoma. CD133+ cells were found to be widely distributed in various types of osteosarcoma tissue. Following cell culture, cells entered the G2/M and S cell cycle stages from G0/G1. Levels of CD133+ cells decreased to normal levels rapidly over the course of cell culture. Colony forming efficiency was higher in the CD133+ compared with the CD133‑ subpopulation of Saos‑2 cells. Expression levels of stem cell‑related genes, including multidrug resistance protein 1 (MDR1) and sex determining region Y‑box 2 (Sox2) in the CD133+ subpopulation of cells were found to be significantly higher compared with the CD133‑ subpopulation. These observations indicate that CD133+ Saos‑2 cells exhibit stem cell characteristics, including low abundance, quiescence and a high potential to undergo differentiation, as well as expression of key stem cell regulatory and drug resistance genes, which may cause osteosarcoma and high drug resistance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242469     DOI: 10.3892/mmr.2012.1231

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  17 in total

1.  Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma.

Authors:  Lei Luo; Ye Liang; Xuemei Ding; Xiaocheng Ma; Guiming Zhang; Lijiang Sun
Journal:  Oncol Lett       Date:  2019-06-06       Impact factor: 2.967

2.  Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer.

Authors:  Edwin E Reyes; Marc Gillard; Ryan Duggan; Kristen Wroblewski; Steven Kregel; Masis Isikbay; Jacob Kach; Hannah Brechka; David J Vander Weele; Russell Z Szmulewitz; Donald J Vander Griend
Journal:  J Transl Sci       Date:  2015-07-30

3.  The expressions of CD133, ALDH1, and vasculogenic mimicry in osteosarcoma and their clinical significance.

Authors:  Zhengqi Bao; Zenong Cheng; Damin Chai
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

4.  Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells.

Authors:  Miaozhong Ni; Min Xiong; Xinchao Zhang; Guoping Cai; Huaiwen Chen; Qingmin Zeng; Zuochong Yu
Journal:  Int J Nanomedicine       Date:  2015-03-31

5.  MicroRNA-29b-1 impairs in vitro cell proliferation, self‑renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells.

Authors:  Riccardo Di Fiore; Rosa Drago-Ferrante; Francesca Pentimalli; Domenico Di Marzo; Iris Maria Forte; Antonella D'Anneo; Daniela Carlisi; Anna De Blasio; Michela Giuliano; Giovanni Tesoriere; Antonio Giordano; Renza Vento
Journal:  Int J Oncol       Date:  2014-08-22       Impact factor: 5.650

Review 6.  Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.

Authors:  Ander Abarrategi; Juan Tornin; Lucia Martinez-Cruzado; Ashley Hamilton; Enrique Martinez-Campos; Juan P Rodrigo; M Victoria González; Nicola Baldini; Javier Garcia-Castro; Rene Rodriguez
Journal:  Stem Cells Int       Date:  2016-06-05       Impact factor: 5.443

7.  Establishment and Characterization of a Human Small Cell Osteosarcoma Cancer Stem Cell Line: A New Possible In Vitro Model for Discovering Small Cell Osteosarcoma Biology.

Authors:  Gaia Palmini; Roberto Zonefrati; Cecilia Romagnoli; Alessandra Aldinucci; Carmelo Mavilia; Gigliola Leoncini; Alessandro Franchi; Rodolfo Capanna; Maria Luisa Brandi
Journal:  Stem Cells Int       Date:  2016-08-29       Impact factor: 5.443

8.  Epidermal growth factor receptor aptamer-conjugated polymer-lipid hybrid nanoparticles enhance salinomycin delivery to osteosarcoma and cancer stem cells.

Authors:  Zuochong Yu; Fangyi Chen; Xiaoxia Qi; Yinmei Dong; Yingying Zhang; Zhe Ge; Guoping Cai; Xinchao Zhang
Journal:  Exp Ther Med       Date:  2017-11-27       Impact factor: 2.447

9.  Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance.

Authors:  Hongyan Ji; Li Chen; Yunpeng Dai; Xiaojun Sun; Xiuli Li; Qi Wang; Daoxin Ma; Dongdong Du; Ping Zhao; Yulin Wang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

10.  A molecular pathology method for sequential fluorescence in situ hybridization for multi-gene analysis at the single-cell level.

Authors:  Linping Hu; Xiuxiu Yin; Jiangman Sun; Anders Zetterberg; Weimin Miao; Tao Cheng
Journal:  Oncotarget       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.